Biotech
What do early data from Utah’s Doctronic AI pilot show?
In this edition of STAT Health Tech: Early data from a Utah pilot using AI to renew prescriptions, Oura files to go public, and more.
Tag
Pharma
Live stream
RIVO news Listen to this section's headlines in an AI voice
Now:
Press play to start the stream
This browser does not support voice playback. Try Chrome, Edge or Safari.
Biotech
STAT+: Five biotech news updates to stay on top of today
Eli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout
Pharma
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial
Pharma
STAT+: Eli Lilly to buy three small vaccine developers
Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.
Business News
Eli Lilly is acquiring three vaccine startups as it makes a push into infectious disease
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs
A STAT Examination
STAT+: How Kyle Diamantas defied expectations as he rose to lead the FDA
WASHINGTON — People in the food world didn’t know what to expect when the Trump administration appointed a little-known Florida attorney as the FDA’s top food official in 2025. They…
First Opinion
Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
Biotech
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
Pharma
STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
Biotech
STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…
Biotech
STAT+: Immunovant shares surge on arthritis trial data
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout